

ESMO Annual Meeting 2023 Yale Participation

Educational Programs

Saturday, Oct 21 at 3:10 PM

Her2+ Breast Cancer

Speaker: Ian Krop

Location: Bilbao Auditorium - NCC

<https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/show/session/56>

Special Sessions

Saturday, Oct 21 at 9:20 PM

Bifunctional small molecules that mediate the degradation of extracellular proteins

Discussant: David Spiegel

Location: Santander Auditorium - Hall 9

<https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/show/session/34>

Monday, Oct 23 at 8:30 AM

Introduction and scientific background to Cancer-related central and peripheral neuropathy

Moderator: Maryam Lustberg

Location: León Auditorium - Hall 7

<https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session/list?q=Maryam+Lustberg&c=s>

Monday, Oct 23 at 9:20 AM

Cancer-related central and peripheral neuropathy – Unmet needs

Speaker: Maryam Lustberg

Location: León Auditorium – Hall 7

<https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session/list?q=Maryam+Lustberg&c=s>

Monday, Oct 23 at 9:20 AM

Bifunctional small molecules that mediate the degradation of extracellular proteins

Speaker: David Spiegel

Location: Santander Auditorium – Hall 9

<https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/show/session/34>

Poster Sessions

Saturday, Oct 21 at 10:55 AM

3770 - A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) with HER2 Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY - Breast (DB) -01, -02, and -03

Location: Barcelona Auditorium - Hall 9

Ian Krop

<https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/show/session/40>

Mini Oral Session

Saturday, Oct 21 at 2:55 PM

1990MO - Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase 2 TROPiCS-03 basket trial

Location: Salamanca Auditorium – Hall 3

Anne Chiang

<https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/show/session/60>

Saturday, Oct 21 at 3:20 PM

1086MO - Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase 2 C-144-01 study

Location: León Auditorium – Hall 7

Harriet Kluger

<https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/show/session/265>

Sunday, Oct 22 at 9:20 AM

Basic Science and Translational Research: Invited Discussant 1209MO and 1210MO

Discussant: Sanjay Aneja

Location: Santander Auditorium – Hall 9

<https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/show/session/81>

Sunday, Oct 22 at 10:55 AM

2365MO - Study EV-103 Cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

Speaker: Daniel Petrylak

Location: Sevilla Auditorium – Hall 9

<https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/show/session/87>

Industry Satellite Symposium

Sunday, Oct 22 at 1:05 PM

Optimising resectable NSCLC outcomes in patients with actionable mutations

Speaker: Roy S. Herbst

Location: Burgos Auditorium – Hall 3

<https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session/list?q=roy+herbst&c=s>